Latest research on Lantus

Insulin glargine is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. It is an analogue of human insulin made by replacing the asparagine residue at position A21 of the A-chain with glycine and adding two arginines to the C-terminus (positions B31 and 32) of the B-chain. The resulting protein is soluble at pH 4 and forms microprecipitates at physiological pH 7.4. Small amounts of insulin glargine are slowly released from microprecipitates giving the drug a long duration of action (up to 24 hours) and no pronounced peak concentration.

Lantus side effects

Sanofi undertook a similar approach with its diabetes drug Lantus to establish that Lantus was not associated with an increased risk of cancer [15] after it was rejected by the German health authority [16]. [source, 2015]
A German cohort study suggested a dose-response relation such that those taking higher doses of insulin glargine (Lantus) had an increased risk for cancer incidence compared with those prescribed human insulin and that both insulin glargine and human insulin were related to an increased risk of cancer incidence and mortality (4). [source, 2013]
Treatment of rats and mice for up to 2 years at doses up to 10-times the normal starting dose of insulin glargine have not suggested an increase in carcinogenicity (Bolli and Owens 2000; Lantus 2004). [source, 2006]